A5063889406- Global Cancer Incidence and Screening
- Colorectal Cancer Screening and Detection
- Economic and Financial Impacts of Cancer
- Lung Cancer Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Global Health and Surgery
- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Health Systems, Economic Evaluations, Quality of Life
- BRCA gene mutations in cancer
- Ethics in Clinical Research
- Healthcare cost, quality, practices
- Genetic factors in colorectal cancer
- Reliability and Agreement in Measurement
Cancer Research UK
2018-2022
Benchmark (United Kingdom)
2019-2022
University College London
2022
Cancer Council Victoria
2022
Cancer Care Ontario
2022
CancerCare Manitoba
2022
International differences in colorectal cancer (CRC) survival and stage at diagnosis have been reported previously. They may be linked to time intervals routes diagnosis. The Cancer Benchmarking Partnership Module 4 (ICBP M4) reports the first international comparison of for patients with CRC from symptom onset until start treatment. Data came 10 jurisdictions across six countries (Canada, UK, Norway, Sweden, Denmark Australia).Patients were identified via registries. on symptomatic screened...
Objective To investigate the relationship between tumour stage at diagnosis and selected components of primary secondary care in diagnostic interval for breast, colorectal, lung ovarian cancers. Methods Observational study based on data from 6,162 newly diagnosed symptomatic cancer patients Module 4 International Cancer Benchmarking Partnership. We analysed odds advanced as a flexible function length (days first presentation to referral) referral diagnosis), respectively, using logistic...
Differences in time intervals to diagnosis and treatment between jurisdictions may contribute previously reported differences stage at survival. The International Cancer Benchmarking Partnership Module 4 reports the first international comparison of routes from symptom onset until start for patients with lung cancer.Newly diagnosed cancer, their primary care physicians (PCPs) cancer specialists (CTSs) were surveyed Victoria (Australia), Manitoba Ontario (Canada), Northern Ireland, England,...
Abstract Background International Cancer Benchmarking Partnership Module 4 reports the first international comparison of ovarian cancer (OC) diagnosis routes and intervals (symptom onset to treatment start), which may inform previously reported variations in survival stage. Methods Data were collated from 1110 newly diagnosed OC patients aged >40 surveyed between 2013 2015 across five countries (51–272 per jurisdiction), their primary-care physicians (PCPs) specialists, supplement by...
To explore differences in position emission tomography-computed tomography (PET-CT) service provision internationally to further understand the impact variation may have upon cancer services. identify areas of exploration for researchers and policymakers optimize PET-CT services improve quality services.Comparative analysis using data based on pre-defined metrics from stakeholders across seven countries. This was informed via document clinical indication guidance expert consensus through...
(Abstracted from Br J Cancer 2022;127:844–854) Ovarian cancer (OC) is the gynecological malignancy with highest mortality, partially attributable to lack of effective screening for early-stage disease. Despite inadequate methods, there exists significant international variation in proportion diagnosed at late stage and OC survival across all stages.
Background: Robust and accurate data underpins cancer research, planning, control comparisons; it shapes the policies structures of health systems internationally. Access to diagnostics is crucial for timely diagnosis treatment planning as previous evidence has shown that delays in can impact outcomes. It possible differences outcomes internationally are a consequence differing levels access diagnostic tests. By better understanding variation this access, relationship be further explored....